Nucleases in homologous recombination as targets for cancer therapy

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

BARTOŠOVÁ Zdenka KREJČÍ Lumír

Year of publication 2014
Type Article in Periodical
Magazine / Source FEBS Letters
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1016/j.febslet.2014.06.010
Field Genetics and molecular biology
Keywords Genomic integrity; Homologous recombination; Nuclease; Inhibitor; Cancer therapy
Description Genomic DNA is constantly challenged from endogenous as well as exogenous sources. The DNA damage response (DDR) mechanism has evolved to combat these challenges and ensure genomic integrity. In this review, we will focus on repair of DNA double-strand breaks (DSB) by homologous recombination and the role of several nucleases and other recombination factors as suitable targets for cancer therapy. Their inactivation as well as overexpression have been shown to sensitize cancer cells by increasing toxicity to DNA-damaging agents and radiation or to be responsible for resistance of cancer cells. These factors can also be used in targeted cancer therapy by taking advantage of specific genetic abnormalities of cancer cells that are not present in normal cells and that result in cancer cell lethality. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info